QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AKTS

QT64Aktis Oncology, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
24.09
+0.56+2.38%
OverviewShort InterestFilings
AKTSQT64Aktis Oncology, Inc.·NASDAQ
OverviewShort InterestFilings
24.09+2.38%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand53.40M
Perf Week23.79%
Market Cap1.26BForward P/E-EPS next Y-2.18Insider Trans-Shs Float-Perf Month30.22%
Enterprise Value896.56MPEG-EPS next Q-0.42Inst Own-Short Float-Perf Quarter33.98%
Income-43981373.00P/S208.39EPS this Y-Inst Trans-Short Ratio-Perf Half Y-
Sales6.03MP/B2.57EPS next Y-33.67%ROA-7.89%Short Interest-Perf YTD-
Book/sh-2.73P/C-EPS next 5Y-ROE-130.27%52W High-Perf Year-
Cash/sh4.25P/FCF-EPS past 3/5Y-ROIC-10.12%52W Low-Perf 3Y-
Dividend Est.-EV/EBITDA-20.50Sales past 3/5Y-Gross Margin89.19%Volatility6.79% 5.40%Perf 5Y-
Dividend TTM-EV/Sales148.68EPS Y/Y TTM-Oper. Margin-923.98%ATR (14)1.71Perf 10Y-
Dividend Ex-Date-Quick Ratio19.49Sales Y/Y TTM-Profit Margin-754.88%RSI (14)67.30Recom1.67
Dividend Gr. 3/5Y-Current Ratio19.49EPS Q/Q-SMA2018.13%Beta1.95Target Price35.33
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA5022.23%Rel Volume2.41Prev Close23.53
Employees79LT Debt/Eq-0.07EarningsSep 02SMA200-Avg Volume229.44KPrice24.09
IPO DateJan 09, 2026Option/ShortNo / YesEPS/Sales Surpr.15.76% -33.33%Net Debt/EBITDA8.23Volume552,078Change2.38%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26InitiatedRaymond JamesStrong Buy$40
Jun-02-26ReiteratedH.C. Wainwright$33 → $35
Mar-09-26InitiatedH.CBuy$30
Feb-03-26InitiatedLeerinkOutperform$31
Jan-04-24DowngradePiper SandlerOverweight → Neutral
Sep-07-23DowngradeB. Riley SecuritiesBuy → Neutral
Sep-18-19DowngradeNorthland Capital MarketsOutperform → Market Perform
Jul-10-19UpgradeNorthland Capital MarketsMarket Perform → Outperform
Feb-05-19DowngradeNorthland Capital MarketsOutperform → Market Perform
Latest News
Jun-16-26
Jun-16-2607:15AM
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For TuesdayBenzinga
05:55AM
Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40Benzinga
Jun-12-26
Jun-12-2607:06PM
Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowSeekingAlpha
10:09AM
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On FridayBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue610
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit610
Selling, General and Administrative Excl. Other13118
Research and Development674126
Other Operating Expense121
Operating Income-75-52-35
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-11-8-6
Net Income Before Taxes-64-44-29
Income Taxes
000
Consolidated Net Income-64-44-29
Net Income From Continuing Operations-64-44-29
Net Income-64-44-29
EPS (Recurring)-1.19-1.26-0.82
EPS (Basic, Before Extraordinaries)-1.19-1.26-0.82
EPS (Diluted)-1.19-1.26-0.82
EBITDA-61-42-27
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin100.00100.00—
Operating Margin-1,250.00-5,200.00—
Net Margin-1,066.67-4,400.00—
Shares Outstanding533535
Market Capitalization
———
Operating Lease Expense
———
Insider Trading Volume
$25.46$22.79$20.12$17.44$14.77● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR